SMi Group are thrilled to present the 2017 8th annual conference on Biosimilars & Biobetters taking place on 27th & 28th September in Central London, UK. As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms creating a rapidly booming biosimilars market. However, as the field of biosimilars evolves, challenges in immunogenicity studies, securing market share, exclusivity and regulations still persist. Created with a top panel of industry thought leaders, Biosimilars & Biobetters 2017 will tackle these challenges head on by honing in on current market trends, emerging opportunities and global developments. Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and critical updates on interchangeability guidelines and patient litigation. Featured speakers include Boehringer Ingelheim, Celltrion Healthcare, QuintilesIMS, Merck Group, Norwegian Medicines Agency, Teva Pharmaceuticals, Biocon, Gedeon Richter, Prolong Pharmaceuticals, Lupin Europe and more! For more information visit the website at http://www.biosimilars-europe.com/gbi or contact the team on email: events@smi-online.co.uk or call +44 (0)20 7827 6000